The Pathophysiology of Schizophrenia Explained

Schizophrenia does not arise from a single broken molecule or a single faulty brain region. Instead, it emerges from overlapping disturbances in brain chemistry, brain structure, immune signaling, and early development that interact across a person’s life. The condition affects roughly one in every hundred people worldwide, and despite decades of research, no single root cause has been pinned down. What researchers have assembled is a layered picture in which dopamine, glutamate, immune proteins, stress hormones, and even gut bacteria each play a role, often amplifying one another in ways that make the whole picture harder to untangle than any one piece.

Dopamine and Why the Classic Theory Needed an Update

For most of the twentieth century, the dominant explanation for schizophrenia centered on dopamine. The logic was straightforward: drugs that block dopamine receptors reduce hallucinations and delusions, and drugs that flood the brain with dopamine can trigger psychosis in healthy people. The original version of this idea, sometimes called the mesolimbic hypothesis, proposed that dopamine pathways projecting from the midbrain to emotional and reward-processing areas were overactive. That story held up for decades, but newer brain-imaging techniques have complicated it. Imaging studies now show that the largest dopamine abnormalities in schizophrenia actually appear in a different set of pathways, those running to the dorsal striatum, a region traditionally linked more to movement and habit learning than to emotion.¹ This does not mean the older theory was entirely wrong, but it has forced researchers to rethink which brain circuits matter most and why antipsychotic drugs, which mainly block dopamine receptors, leave many symptoms only partially treated.

The limits of dopamine-focused thinking become especially clear when you consider the symptoms that current medications handle poorly. Hallucinations and paranoia (the so-called positive symptoms) often respond to dopamine-blocking drugs, but cognitive problems like poor working memory and the emotional flatness and social withdrawal classified as negative symptoms tend to persist. That gap between what dopamine-targeted drugs fix and what they leave untouched pushed researchers to look at other neurotransmitter systems.

Glutamate and NMDA Receptors

Glutamate is the brain’s main excitatory chemical messenger. One of its key receptors, the NMDA receptor, plays a central role in learning, memory, and the fine-tuning of neural circuits. Two decades of converging evidence from genetics, pharmacology, and biochemistry point to underperformance of NMDA receptors as a major contributor to schizophrenia’s disease process.² The clue that started this line of research came from the drug PCP (and later ketamine), which blocks NMDA receptors and produces a strikingly complete imitation of schizophrenia in healthy volunteers, including not just hallucinations but also cognitive deficits and emotional blunting that dopamine-based models never fully explained.

What makes NMDA receptor problems so consequential is that they sit upstream of many other disturbances. When NMDA receptors on certain inhibitory brain cells do not work properly, those cells fail to keep excitatory neurons in check. The result is a cascade: too much unregulated excitation in some circuits, too little coordinated signaling in others, and downstream changes in dopamine release that circle back to the classic dopamine abnormalities.³ In other words, the dopamine problems may partly be a consequence of glutamate problems rather than the other way around.

Fast-Spiking Interneurons and Disrupted Brain Rhythms

A specific class of inhibitory brain cells called parvalbumin-positive interneurons has emerged as a critical weak link. These cells fire rapidly and precisely, and their activity generates gamma oscillations, a type of fast electrical rhythm that the brain uses to bind information together during tasks like paying attention and holding items in working memory. In schizophrenia, these interneurons appear to be less active than normal, and the gamma oscillations they produce are consistently abnormal across multiple brain regions.⁴

A telling example comes from working memory tasks. In healthy people, gamma power in the prefrontal cortex ramps up when they need to hold information in mind. In people with schizophrenia, that increase does not happen.⁴ The failure is not just a marker of illness; it tracks with the severity of cognitive symptoms. Abnormalities in the inhibitory system that drives these rhythms, particularly involving the neurotransmitter GABA, are thought to be responsible for the disruption.⁵ This connects directly to the NMDA story, because parvalbumin interneurons are especially dependent on NMDA receptor input to function properly.

Synaptic Pruning and the Complement System

One of the most striking findings of the past decade links schizophrenia risk to the immune system’s involvement in brain development. During adolescence, the brain normally eliminates excess synapses in a process called synaptic pruning, sculpting neural circuits to work more efficiently. A landmark genetics study found that variants in the gene for complement component 4 (C4), part of the immune system’s molecular tagging machinery, were strongly associated with schizophrenia risk. The key finding was that gene variants promoting higher expression of the C4A protein in the brain carried greater risk, and that C4 protein was found at synapses, dendrites, and axons in human brain tissue. In mice, C4 actively drove synapse elimination during early postnatal development.⁶

Follow-up work has explored how excess C4 causes synapse loss. Overexpression of C4 in the mouse cortex reduced the density of dendritic spines, the tiny protrusions where synapses form, by roughly 16 to 22 percent.⁷ And in postmortem human brains, C4 protein is overexpressed in several regions of the cortex in people who had schizophrenia, supporting the idea that excessive complement activity disrupts pruning during the adolescent period when the illness typically first appears.⁸ This line of research helps explain a longstanding puzzle: why schizophrenia tends to emerge in late adolescence, right when pruning peaks.

What Brain Scans Reveal

Structural brain imaging paints a consistent picture. A meta-analysis comparing people with chronic schizophrenia to healthy controls found significantly lower total brain and total grey matter volumes, along with smaller volumes in the frontal lobes, prefrontal cortex, superior temporal gyri, and hippocampi on both sides. The fluid-filled ventricles deep inside the brain were significantly enlarged.⁹ These are not subtle statistical quirks; they appear reliably across large studies and are visible on standard MRI.

The changes are also progressive. Over a five-year period, people with schizophrenia showed excessive thinning of the cortex compared to controls, particularly in the frontal and temporal lobes, with no areas showing compensatory thickening.¹⁰ An important and uncomfortable caveat is that antipsychotic medications themselves may contribute to some of these structural changes. A recent study of people with treatment-resistant schizophrenia starting clozapine found that the drug was associated with grey matter volume reductions in the amygdala, hippocampus, thalamus, and other subcortical structures, as well as further ventricular enlargement and widespread cortical thinning.¹¹ Separating the effects of the illness from the effects of its treatment remains one of the field’s trickiest challenges.

White Matter and Wiring Problems

Grey matter gets most of the attention, but the brain’s white matter, the insulated cable bundles connecting distant regions, is also affected. Imaging studies and postmortem examinations have documented reduced myelin content, altered alignment of nerve fibers, and decreased expression of several genes involved in producing myelin in the brains of people with schizophrenia.¹²

The problem appears to lie not in outright destruction of myelin sheaths but in faulty construction. Researchers describe this as dysmyelination rather than demyelination: the myelin is poorly made or structured from the start rather than being attacked and broken down as it is in conditions like multiple sclerosis.¹³ Under the electron microscope, the oligodendrocytes responsible for making myelin show swelling, loss of internal structures, and accumulation of waste products.¹⁴ If you think of grey matter as the processing centers and white matter as the highways between them, schizophrenia involves both degraded processors and poorly maintained roads.

The Stress System and Neuroinflammation

The body’s stress response system, the hypothalamic-pituitary-adrenal (HPA) axis, is overactive in many people at the onset of schizophrenia. A systematic review of first-episode, drug-naive patients found that roughly three-quarters of those studied had elevated baseline cortisol levels compared to healthy controls, and their stress response appeared blunted, meaning the system was stuck in a high-output state and could not react normally to new stressors.¹⁵¹⁶ Chronic cortisol elevation is not benign. It can damage the hippocampus, worsen inflammation, and interact with dopamine and glutamate signaling in ways that amplify the other pathological processes already described.

Alongside the stress axis, there is growing evidence of neuroinflammation. Microglia, the brain’s resident immune cells, show increased density and activation at various stages of the illness.¹⁷ Activated microglia can damage neurons and synapses, promote oxidative stress, and sustain the kind of low-grade inflammation that may drive progressive brain changes over time. Whether microglial activation is a cause of the illness, a response to it, or both is still debated, but its presence adds another layer to the pathology.

Oxidative Stress as a Connecting Thread

Many of the individual disturbances in schizophrenia converge on oxidative stress, an imbalance between harmful reactive molecules and the brain’s ability to neutralize them. A comprehensive review found that oxidative stress is intimately linked to inflammation, oligodendrocyte abnormalities, mitochondrial dysfunction, NMDA receptor underperformance, and impaired parvalbumin interneurons, essentially tying together many of the threads described above.¹⁸

Animal experiments reinforce this idea. In a mouse model of NMDA receptor dysfunction, early-life blockade of these receptors produced lasting changes in the ratio of protective to harmful glutathione molecules in the prefrontal cortex, reduced parvalbumin expression, and impaired mitochondrial function in a cell-type-specific way. Treating these animals with antioxidants prevented some of the mitochondrial and synaptic changes.¹⁹ These findings suggest that oxidative stress is not just a bystander but actively pushes the disease process forward, and that targeting it might, in principle, slow some of the damage. Clinical translation, however, has been slow.

Genetics, Environment, and the Multi-Hit Model

Schizophrenia runs in families, and twin studies show a substantial heritable component. Yet genome-wide screens have not identified a single gene that causes the condition on its own. Instead, the picture that has emerged is one of many weakly acting gene variants that cumulatively raise risk, along with a role for epigenetic changes, modifications to how genes are read without altering the DNA sequence itself.²⁰ Larger structural rearrangements of DNA, called copy number variants, also contribute. The deletion at chromosome 22q11, for instance, is widely considered the single largest known genetic risk factor for schizophrenia, and at least sixteen other such variants have been linked to increased risk.²¹

Genetics alone, though, is not destiny. The prevailing framework is a multi-hit model: genetic vulnerability acts as a first layer, and environmental insults such as maternal infection during pregnancy, childhood stress, or drug use during adolescence serve as additional hits that push the brain over a threshold into illness.²² Viral infections during pregnancy fit into this model especially well, as they can interact with both immune and neurodevelopmental vulnerabilities to amplify risk.²³ No single hit is sufficient on its own for most people; it is the accumulation that matters.

Predictive Coding and the Brain’s Internal Model

A more recent theoretical framework tries to explain how all these molecular and cellular abnormalities translate into the actual experience of psychosis. Under the predictive coding account, the brain constantly generates predictions about what it expects to see, hear, and feel, then compares those predictions against incoming sensory data. When there is a mismatch, the resulting “prediction error” updates the brain’s internal model. In schizophrenia, the precision assigned to prior beliefs may be abnormally low relative to sensory signals, leading to maladaptive inferences about reality.²⁴

In practical terms, this means the brain may treat noise as meaningful signal. An ambiguous sound becomes a voice. A coincidence becomes a conspiracy. The molecular disturbances described earlier, particularly NMDA receptor dysfunction and disrupted gamma oscillations, fit naturally into this framework because both impair the brain’s ability to generate and maintain stable predictions. Predictive coding does not replace the neurochemical models; it sits on top of them as a description of what goes wrong at the computational level.

The Gut-Brain Axis

An emerging area of research connects the gut microbiome to schizophrenia. Disruptions in the gut’s microbial community can alter the metabolites those bacteria produce, which in turn can compromise the blood-brain barrier and promote neuroinflammation.²⁵ Studies have found unexpected relationships between specific gut bacteria and inflammatory markers in people with schizophrenia. One analysis reported that a bacterium typically associated with anti-inflammatory properties, Succinivibrio, was instead positively correlated with several pro-inflammatory markers in patients, suggesting the usual gut-immune relationship may be disrupted.²⁶

The gut-brain axis remains one of the most speculative areas of schizophrenia research. Most of the data is correlational, and nobody has demonstrated that fixing gut bacteria can meaningfully improve psychotic symptoms. Still, the connections to inflammation and blood-brain barrier integrity give the hypothesis biological plausibility, and it may eventually offer a window into why metabolic problems like diabetes and obesity are so common in people with schizophrenia even before they start medications known to cause weight gain.

Why Smoking Rates Are So High

People with schizophrenia smoke cigarettes at dramatically higher rates than the general population. This is not simply a lifestyle coincidence. Research suggests it may reflect a biological attempt at self-medication. Schizophrenia is associated with a reduction in a specific type of nicotinic receptor, the alpha-7 subtype, in the hippocampus. These receptors are involved in attention and the brain’s ability to filter out irrelevant sensory input. Nicotine from cigarettes delivers a chemical that activates whatever alpha-7 receptors remain, temporarily improving some of the sensory gating deficits that plague people with the condition.²⁷ The cost, of course, is all the health damage smoking brings with it. This finding has spurred interest in developing drugs that target alpha-7 receptors without the harm of tobacco.

Treatments Beyond Dopamine Blockade

For over sixty years, every approved antipsychotic drug worked primarily by blocking dopamine receptors. That changed in September 2024 when the U.S. Food and Drug Administration approved xanomeline/trospium chloride, the first antipsychotic that works through an entirely different mechanism. Instead of blocking dopamine, xanomeline activates muscarinic receptors, specifically the M1 and M4 subtypes, which are part of the acetylcholine signaling system. Evidence suggests that an imbalance in the expression of these receptors contributes to schizophrenia’s symptoms.²⁸ The approval was based on three randomized, placebo-controlled trials and two long-term safety trials, and the drug showed significant reductions in both positive and negative symptom scores, with improvements appearing within two weeks.²⁹

The trospium chloride component is paired with xanomeline specifically to block muscarinic activation in the rest of the body, reducing side effects like nausea and excessive salivation that derailed earlier attempts to develop muscarinic drugs. The approval matters beyond any one medication because it validates the idea that schizophrenia involves multiple neurotransmitter systems, not just dopamine. Ongoing research into drugs targeting glutamate receptors, GABA signaling, and nicotinic receptors reflects the same principle: the pathophysiology is multi-system, so treatments eventually will need to be too.